LONDON (Reuters) - Cheaper "biosimilar" copies of expensive biotech drugs received a boost in Britain on Tuesday when the country's health cost-effectiveness agency NICE said patients needing such medicines "should be started with the least expensive drug".
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire